SciSparc Ltd., a clinical-stage pharmaceutical company, announced on February 29, 2024, the successful delivery of its SCI-210 treatment for a clinical trial targeting Autism Spectrum Disorder (ASD) in pediatric patients. The trial, to be conducted at the Soroka Medical Center, will test the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. SCI-210 is a proprietary combination of cannabidiol-rich oil and CannAmide, SciSparc's palmitoylethanolamide-based tablets. The randomized, double-blind, placebo-controlled trial with cross-over will span 20 weeks and enroll 60 children. Primary efficacy endpoints include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement scale, and determining the effective therapeutic dosage. SciSparc's CEO, Oz Adler, expressed confidence in the treatment's potential to offer a more effective and safe option for patients. The company aims to proceed with the commercialization of SCI-210 in Israel following the trial's outcome. The press release also serves as a forward-looking statement and is incorporated by reference into the company's registration statements filed with the SEC.

SciSparc Ltd., a clinical-stage pharmaceutical company, announced on February 29, 2024, the successful delivery of its SCI-210 treatment for a clinical trial targeting Autism Spectrum Disorder (ASD) in pediatric patients. The trial, to be conducted at the Soroka Medical Center, will test the safety, tolerability, and efficacy of SCI-210 compared to CBD monotherapy. SCI-210 is a proprietary combination of cannabidiol-rich oil and CannAmide, SciSparc's palmitoylethanolamide-based tablets. The randomized, double-blind, placebo-controlled trial with cross-over will span 20 weeks and enroll 60 children. Primary efficacy endpoints include the Aberrant Behavior Checklist-Community, the Clinical Global Impressions-Improvement scale, and determining the effective therapeutic dosage. SciSparc's CEO, Oz Adler, expressed confidence in the treatment's potential to offer a more effective and safe option for patients. The company aims to proceed with the commercialization of SCI-210 in Israel following the trial's outcome. The press release also serves as a forward-looking statement and is incorporated by reference into the company's registration statements filed with the SEC.